ARTICLE | Company News

Sequenom, Illumina deal

December 8, 2014 8:00 AM UTC

Illumina and Sequenom partnered to access a shared pool of the companies’ IP related to nucleic acid analysis technologies for non-invasive prenatal testing (NIPT). Illumina will pay Sequenom $50 million up front for exclusive, worldwide rights to develop and commercialize in vitro diagnostic (IVD) kits using the shared IP pool. Illumina will also have exclusive, worldwide rights to license the shared IP to third-party laboratories wishing to develop their own laboratory-developed tests (LDTs). Illumina will pay Sequenom royalties on sales of IVD kits. Sequenom and Illumina will each have non-exclusive rights to access the pool to develop and sell LDTs. The partners will share revenue from products developed using the shared IP, plus royalties on third-party licenses. Sequenom said the shared pool will contain more than 400 patents and patent applications. ...